Hoth Therapeutics (NASDAQ:HOTH) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Hoth Therapeutics (NASDAQ:HOTH) in a report issued on Thursday morning,Benzinga reports. The firm currently has a $5.00 price objective on the stock.

Separately, Wall Street Zen upgraded Hoth Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 31st. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Hoth Therapeutics currently has a consensus rating of “Buy” and an average price target of $4.00.

Hoth Therapeutics Stock Up 7.6%

Shares of HOTH opened at $1.42 on Thursday. The business has a 50-day simple moving average of $0.91 and a two-hundred day simple moving average of $1.02. The stock has a market cap of $18.76 million, a price-to-earnings ratio of -1.08 and a beta of 0.55. Hoth Therapeutics has a 52 week low of $0.58 and a 52 week high of $3.80.

Hoth Therapeutics (NASDAQ:HOTH) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.27) EPS for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.07. On average, equities analysts anticipate that Hoth Therapeutics will post -1.36 earnings per share for the current fiscal year.

Institutional Trading of Hoth Therapeutics

An institutional investor recently raised its position in Hoth Therapeutics stock. Geode Capital Management LLC increased its holdings in shares of Hoth Therapeutics, Inc. (NASDAQ:HOTH) by 15.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 95,946 shares of the company’s stock after purchasing an additional 13,038 shares during the quarter. Geode Capital Management LLC owned approximately 1.39% of Hoth Therapeutics worth $72,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 7.08% of the company’s stock.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.